HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Pancreatic cancer — a changing outlook if diagnosed early
-
- Should gemcitabine plus nab-paclitaxel be used in the adjuvant pancreatic cancer setting?
- Reflections on my 30th ASH Annual Meeting John Sweetenham, MD, FRCP, FACP
- ASCO updates recommendations on venous thromboembolism prevention, treatment for patients with cancer
- Antibody-drug conjugate provides ‘unprecedented’ benefit in metastatic HER2-positive breast cancer
- Addition of S-1 to adjuvant endocrine therapy increases invasive DFS in breast cancer subset
- Menopausal hormone therapy regimens have opposite lasting effects on breast cancer incidence
- Sutimlimab demonstrates ‘rapid, sustained’ responses in cold agglutinin disease
- Bispecific CAR T-cell therapy safe, effective for advanced multiple myeloma
-
- Patients with CLL face ‘substantial burden’ of adverse events in real-world treatment setting
- Researchers honored at San Antonio Breast Cancer Symposium
- Invasive prostate cancer incidence rising among young men; cause elusive
- Nivolumab shows promise in recurrent or metastatic cervical, vaginal/vulvar cancers
- Flu vaccination shows modest efficacy among patients with cancer
- FDA approves Reblozyl for beta-thalassemia
- FDA approves Ziextenzo, biosimilar to pegfilgrastim
- FDA grants fast track designation to bemcentinib for acute myeloid leukemia
-
- FDA approves Enhertu for HER2-positive breast cancer
- Surgeon receives Association of Community Cancer Centers’ clinical scientist award
- International Association for the Study of Lung Cancer appoints chief science officer